Frequently Asked Questions

Yes, the CHTN can serve investigators outside of North America. The CHTN does reserve the right to handle these requests on a case-by-case basis and each division that can potentially serve the request must follow their institutions’ specified rules and regulations for shipping specimens internationally. Please contact the CHTN Central Coordinator, Kiley Radin at kradin@chtn.org to begin the process.

Yes, it is SCR_004446

The CHTN is not a bank and therefore does not have a catalog of biospecimens. The CHTN is a prospective collection service. However, some biospecimens are banked for a limited time. Banked biospecimens that meet an investigator's request will be made available.

At this time, the CHTN does not charge an application fee. The CHTN only charges a nominal processing fee for its services and specimens. The NCI’s grant support for the CHTN allows us to offer a reduced rate for investigators affiliated with academic, government, and non-commercial entities. Please click here for our current processing fees.

Yes, all active CHTN investigators with open/active requests are responsible for all fees associated with any biospecimens procured for them until the request is inactivated by the investigator. This includes biospecimens that are refused without appropriate justification, especially biospecimens specifically collected to fill individual request protocols, and blood even if the tissue is necrotic or unavailable. Because the CHTN is a prospective procurement program, resources are allocated for the collection of biospecimens requested by investigators. Therefore, the CHTN expects investigators to accept the biospecimens that were collected on their behalf to fulfill their active protocols. Failure to accept procured samples may result in penalties to the principal investigator or his/her institution, including but not limited to, loss of access to future services from the CHTN.

Yes, the CHTN accepts credit card payments, PO numbers and checks.

Information is based on the type of biospecimen provided. Standard information for all biospecimens includes the age, race and gender of the patient as well as the quality control diagnosis of the tissue. Also included with the samples are copies of the corresponding pathology reports from which all identifying information has been removed. Copies of these reports are sent along with the biospecimens with the exception of specimens shipped on the same day of collection. The reports for these biospecimens will be provided once they are available.

A set of basic clinical and demographic information is included with each specimen distributed. Chart Review to obtain additional de-identified information from the patient medical record may be requested at additional cost and subject to some limitations, which will need further discussion with your division coordinator. The CHTN performs data abstraction and de-identification only and not medical interpretation.

The CHTN Divisions are located at large academic medical centers which provide tertiary care. Many patients who undergo treatment at our hospitals are referred by other providers. Those patients may not receive their primary care, initial treatment or follow-up care at our institutions. Medical records the CHTN has access to are limited to those electronic records at our own hospitals, and those records may be absent or incomplete for referral patients and patients who change providers. The CHTN is unable to provide imaging data, such as radiographs, because image files contain embedded patient identifiers which cannot be readily removed. The CHTN does not directly interact with specimen donors or their caregivers to obtain medical information, nor do we re-contact specimen donors. Therefore, the CHTN cannot guarantee specific data elements, follow-up, or outcome information will be available when performing a Chart Review, and we cannot represent the data provided from a Chart Review as being complete.

CHTN Divisions also obtain specimens through arrangements with other hospitals or providers. There are limitations on the clinical data these subsites are allowed to provide, and the donor may also be de-linked when the specimen is transferred to the CHTN. A CHTN Division's IRB may also require de-linking of some donors when releasing a specimen to an investigator. Requests for non-standard clinical data and requests for chart review made after the specimen is provided are not possible in these cases.

Investigators requiring non-standard clinical data, who require follow-up or outcome information, or who anticipate a future need to request chart information after a specimen is received must document this at the time of the original specimen request so the CHTN can attempt to exclude specimens unlikely to have this information available. Users should be aware that such requests may result in access to fewer specimens. A Chart Review fee will apply for each review attempted.

No, the CHTN does not provide cells, cell separation, or cell culture services. However, the CHTN is able to provide fresh viable tissue specimens suitable for these applications. If you are requesting cells or cell cultures, please consider contacting the American Type Culture Collection (ATCC) or the NCI Specimen Resource Locator.

The CHTN has access to remnant blood from the clinical laboratories, and there are several CHTN divisions that have access to consented patient populations in which blood/blood products can be obtained specifically for research purposes. There may be limitations on the volume a division can supply based on the need for patient diagnosis or IRB restrictions, which may limit the number of milliliters obtained for research. The CHTN Coordinator responsible for your geographic location will answer questions regarding availability and specifics regarding the collection and processing. If an investigator requires large amounts (i.e. 10 ml) of blood or blood products, the investigator can find more information about the availability of these samples from the NCI Specimen Resource Locator.

The CHTN has a range of tissue microarray (TMA) slides available, which include surveys of normal tissues and several common cancers. These arrays are suitable as preliminary screening tools or to supplement other findings. Detailed clinical annotation, treatment and outcome are not provided. Our available TMA designs change based on feedback we receive from researchers, but the CHTN does not custom fabricate TMA blocks for individual projects. Please visit the CHTN TMA web site for more information.

Biospecimens are distributed on a rotating basis using the following priority order:

1. Peer-review funded investigators at academic or non-profit institutions, requests associated with peer-review funded projects at commercial and for-profit companies, investigators at federal & national laboratories.
2. Developmental and new investigators at academic centers or non-profit research institutions.
3. Other investigators including those who are associated with for-profit research institutions.

Discretion will be used by the various divisions to determine when to deviate from the above outlined priority system. If an investigator wishes to appeal his/her priority, that investigator can write a letter to the Coordinating Committee or the NCI Program Director. Internal investigators at all contributing institutions should retain the highest priority.

Because we operate as a prospective service, the answers to these questions vary with each request. Investigators are asked to provide us with a minimum to maximum size that they can use. For cancers, the amount of tissue available varies by the anatomic site and diagnosis. Many cancers are resected at an early stage and will have very little tissue available. A reasonable amount to request for a breast or pancreatic cancer is 150-250 mg. Bulky tumors such as ovary or colon cancers may yield more tissue than this. Banked fluids are typically stored in aliquots of 1ml for whole blood or urine and .25 to 0.5 ml for plasma or serum. The smaller the sample size that you can accept, the more samples will be available. Requests for larger samples are harder to fulfill because the CHTN will fill requests for smaller samples first in order to serve as many investigators as possible. You may specify a specific number of samples you would like, or you may have an open-ended request. The length of time it takes to serve a request is impossible to estimate. It will depend upon the requirements of your protocol, the availability of the samples requested, and the number of investigators requesting the same tissue type.

The CHTN does NOT provide fetal tissue (including tissue from fetal autopsies) to investigators because of concerns about differences in individual state laws and concerns about potential use for stem cell research.

The five adult-specimen institutions that comprise the CHTN divisions are The University of Pennsylvania, The University of Virginia, the University of Alabama at Birmingham, Vanderbilt University Medical Center, and The Ohio State University. The CHTN has one division that specializes in the procurement and distribution of pediatric tissues, Nationwide Children's Hospital in Columbus, Ohio. Each of the divisions has arrangements with their institutional hospitals, local hospitals and other subcontract hospitals to collect biospecimens.

No, an investigator cannot specify the percentage of tumor in a specimen, but the CHTN guarantees at least 10% tumor in a tumor specimen. A specimen can be enriched by macrodissection for an additional charge. Please contact your primary division to discuss this service in further detail.

No, the CHTN does not perform clinical tests on tissue (e.g. for the presence of infective agents such as hepatitis). While the CHTN attempts to avoid providing tissues that are contaminated with highly infectious agents such as hepatitis and HIV, all tissues should be handled as if potentially infectious. Recipients must also agree not to perform such tests on the tissues supplied by the CHTN. If an institution tests samples or byproducts for infectious diseases, the CHTN does not accept any information regarding the results of these tests.

An authorized signature is the signature from someone other than the applying PI who is responsible for the applying investigator and his/her research. For academic investigators, an official from your Office of Research or Technology Transfer Office is acceptable. For commercial investigators, the CEO or representative from your legal department is acceptable.

Your primary division will review your request(s) and determine whether it can be served locally. If not, your request(s) will be shared with the other divisions (networked). If your request is networked, a CHTN divisional representative will contact you when samples become available to arrange shipping from that division.

The CHTN's Agreement for Use of Tissue states that investigators agree to acknowledge the contributions of the Cooperative Human Tissue Network in all publications resulting from the use of these tissues. The CHTN’s Research Resource Identifier (RRID) is SCR_004446. The following is one suggestion on how to acknowledge the CHTN:

Tissue samples were provided by the NCI Cooperative Human Tissue Network (CHTN). Other investigators may have received specimens from the same tissue specimens.

The CHTN provides the T, N and M (where applicable) categories staging, according to American Joint Commission on Cancer (AJCC) criteria. Clinical staging requires clinical information that is generally not available to the CHTN when biosamples are procured. To provide clinical staging information associated with biosamples, investigators will be charged a chart review to obtain this data.

Yes, the CHTN has the following four tube types on hand; K2 EDTA (purple top), Sodium Heparin (dark green top), Serum Separator Tube - clot activator (red top) and NaCitrate 3.5 (light blue top). If a different tube type is needed for your collection, then we would consider that investigator supplied and the investigator would need to send the tubes to the division(s).

Each CHTN division follows not only their institutional data retention policy, which ranges from three to ten years of required storage depending on the division, but also the data retention guidelines set by government entities (i.e., National Cancer Institute). “Data” in this context includes the following items pathology reports, investigator applications and agreements, financial records, administrative records, MTAs, IRB and regulatory records, and scientific, biospecimen and QMS records. If you need to know the exact policy at a certain division, please reach out to the division coordinator.

Please review the CHTN Biomarker Policy for more information

The Cooperative Human Tissue Network (CHTN) takes the responsibility to protect the safety and security of an Investigator’s research and personal data, such as applications, projects, tissue requests and data. The CHTN will not release Investigator’s information to other CHTN Investigators or resources that are not directly related to the operations of the network. CHTN operates as a network and shares Investigator information only among the CHTN sites for the purpose of fulfilling an Investigator’s request.

For the evaluation of our program the CHTN also must disclose research abstracts to our funding resource, the National Cancer Institute (NCI).